BackgroundEven with the advent of new systemic therapy options, radiotherapy keeps its place for the treatment of endocrine and neuroendocrine tumors. The advancement of radiotherapy technology has enabled its advent into the treatment of rare tumor entities.Materials and methodsA selective PubMed search was performed and national and international guidelines were taken into consideration.ResultsEndocrine and neuroendocrine tumors are rarely treated by definitive radiotherapy. For anaplastic thyroid carcinomas and aggressive pituitary tumors, radiotherapy represents a cornerstone of multimodal treatment. Locally advanced neuroendocrine tumors (NET) can be treated with concomitant radiochemotherapy. Stereotactic ablative radiotherapy is applied in oligometastatic cases. In palliative situations, radiotherapy is successfully used for symptom relief.ConclusionDespite advances in systemic therapy options for treatment of endocrine and neuroendocrine tumors, the field of radiation therapy continues to offer a broad spectrum of therapies from curative to palliative situations, including oligometastasis. The decision for radiotherapy treatment should be made by a multidisciplinary team.